Skip to main content
. 2017 May 3;15(6):4005–4014. doi: 10.3892/mmr.2017.6546

Figure 3.

Figure 3.

SFN prevents BLM-induced lung fibrosis. (A) Masson's trichrome staining of lung tissues from various treatment groups on days 7 and 28 post-treatment. BLM induced marked lung fibrosis and collagen deposition at day 28, which was alleviated by SFN treatment. Magnification, ×200. (B) The Szapiel fibrosis score was lower in the BLM/SFN group, compared with the BLM group at day 28. (C) Hydroxyproline content was quantified by on days 7 and 28. The hydroxyproline content of BLM group was higher than the control group at day 28, which was reduced by SFN treatment. (D) Western blot analysis for TGF-β was used to demonstrate the effect of SFN on BLM-induced lung fibrosis at day 7 and 28 post-treatment. Data are presented as the mean ± standard deviation (n=6/group). #P<0.05 vs. control group; *P<0.05 vs. BLM group. BLM, bleomycin; SFN, sulforaphane; TGF-β, transforming growth factor-β; Ctrl, control.